Genetic Polymorphisms of Toll-like receptors 2 and 9 as Susceptibility Factors for the Development of Ankylosing Spondylitis and Psoriatic Arthritis by Camila F. Oliveira-Toré, Amarilis G. Moraes, Gabriela F. Martinez, Janisleya S. F. Neves, Luciana C. Macedo, Marco A. Rocha-Loures, Marília G. Quirino, Hugo V. Alves, Ana M. Sell, Jeane E. L. Visentainer

“…Ankylosing spondylitis (AS) and psoriatic arthritis (PsA) are classified as spondyloarthritis (SpA), a group of inflammatory rheumatic diseases with complex genetic etiology. …”
Get full text

S-Calprotectin (S100A8/S100A9): A Potential Marker of Inflammation in Patients with Psoriatic Arthritis by Claes Hansson, Catharina Eriksson, Gerd-Marie Alenius

“…In multiple logistic regression analysis, S-calprotectin was the only variable significantly associated with psoriatic arthritis (P=0.002, OR=1.006, 95% CI = 1.002–1.010). …”
Get full text

Ultrasound Findings in Hand Joints Involvement in Patients with Psoriatic Arthritis and Its Correlation with Clinical DAS28 Score by Priyanka Naranje, Mahesh Prakash, Aman Sharma, Sunil Dogra, Niranjan Khandelwal

“…To determine the frequency of the various ultrasound findings in hand joints in patients with psoriatic arthritis and correlate grayscale and Power Doppler ultrasonography findings with Disease Activity Score 28. …”
Get full text

Apremilast generic for the treatment of active psoriatic arthritis: A single-center real-life experience from India by Sanjiv Amin, Aneesa Kapadia, Dhiraj Dhoot, Hanmant Barkate

“…Introduction: Apremilast has been recently introduced in the treatment of adult psoriatic arthritis (PsA) patients in India. Its efficacy and safety have been established in the landmark clinical trials; however, there is still a dearth of its real-world experience in the management of PsA in India. …”
Get full text

Efficacy and safety of Janus kinase inhibitors in the treatment of psoriasis and psoriatic arthritis: An analysis of evidence from 2014 to 2022 by Jiao Wang, Tian Ma, Xiaoying Sun, Liu Liu, Seokgyeong Hong, Huijung Cha, Miao Zhang, Jiale Chen, Naixuan Lin, Bin Li, Xin Li

Subjects: Get full text

Evaluation of the “Multivariable Psoriatic Arthritis Risk Estimation Tool” in a Cohort of Patients with Psoriasis: Preliminary Results of a Prospective Observational Study by Ennio Lubrano, Filomena Mandato, Marcella Antenucci, Fabio Massimo Perrotta

Subjects: “…Psoriatic arthritis…”
Get full text

Differences in the response to TNF inhibitors at distinct joint locations in patients with psoriatic arthritis: results from nine European registries by Adrian Ciurea, Seraphina Kissling, Andrea Götschi, Lykke Midtbøll Ørnbjerg, Simon Horskjær Rasmussen, Bálint Tamási, Burkhard Möller, Michael J. Nissen, Bente Glintborg, Anne Gitte Loft, Almut Scherer, René Bräm, Karel Pavelka, Jakub Závada, Joao Madruga Dias, Paula Valente, Bjorn Gudbjornsson, Olafur Palsson, Vappu Rantalaiho, Ritva Peltomaa, Catalin Codreanu, Corina Mogosan, Florenzo Iannone, Marco Sebastiani, Gareth T. Jones, Gary J. Macfarlane, Isabel Castrejon, Ziga Rotar, Brigitte Michelsen, Johan K. Wallman, Irene van der Horst-Bruinsma, Oliver Distler, Mikkel Østergaard, Merete Lund Hetland, Raphael Micheroli, Caroline Ospelt

“…Abstract Background Efficacy of tumour necrosis factor inhibitors (TNFi) for peripheral arthritis in patients with psoriatic arthritis (PsA) has been established in randomized clinical trials that have used improvement in summated joint counts as an outcome. …”
Get full text

Minimal disease activity and associated factors in patients with psoriatic arthritis: cross-sectional study from a single center by Murat Bektas, Berk Çelik, Burak İnce, Yasemin Yalçınkaya, Bahar Artım Esen, Ahmet Gül, Murat İnanç

Subjects: “…psoriatic arthritis…”
Get full text

Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA Registry by Giuseppe Lopalco, Maria Morrone, Fabiola Atzeni, Chiara Bazzani, Francesco Paolo Bianchi, Francesco Paolo Cantatore, Roberto Caporali, Antonio Carletto, Alberto Cauli, Maria Sole Chimenti, Sergio Colella, Fabrizio Conti, Addolorata Corrado, Ennio Giulio Favalli, Alberto Floris, Marco Fornaro, Rosario Foti, Roberta Foti, Elena Fracassi, Bruno Frediani, Stefano Gentileschi, Roberto Gorla, Elisa Gremese, Emanuela Praino, Roberta Ramonda, Cinzia Rotondo, Marco Sebastiani, Angelo Semeraro, Gianfranco Ferraccioli, Giovanni Lapadula, Florenzo Iannone

“…Background: Randomized clinical trials have demonstrated the efficacy of secukinumab (SECU) in reducing disease activity in psoriatic arthritis (PsA), while real-world studies prove a broader perspective on SECU’s usefulness in everyday clinical practice. …”
Get full text

Single-cell RNA sequencing of circulating immune cells supports inhibition of TNFAIP3 and NFKBIA translation as psoriatic arthritis biomarkers by Ameth N. Garrido, Rohan Machhar, Omar F. Cruz-Correa, Darshini Ganatra, Sarah Q. Crome, Sarah Q. Crome, Joan Wither, Joan Wither, Joan Wither, Igor Jurisica, Igor Jurisica, Igor Jurisica, Dafna D. Gladman, Dafna D. Gladman, Dafna D. Gladman

Subjects: “…psoriatic arthritis…”
Get full text

Do individuals with inflammatory arthritis receive minimally adequate treatment for incident depression and anxiety: A population-based study by Alyssa Howren, Eric C. Sayre, J. Antonio Avina-Zubieta, Joseph H. Puyat, Deborah Da Costa, Hui Xie, Eileen Davidson, Amit Gupta, Mary A. De Vera

Subjects: Get full text

Low apolipoprotein A1 and high apolipoprotein B levels indicate specific lipid changes in treatment naïve early psoriatic arthritis by Kurt de Vlam, Rik Lories, M Van Mechelen, Sofia Pazmino, P Verschueren, Barbara Neerinckx, Lies Storms, Alla Ishchenko

“…Objectives To investigate serum lipid profile in early, treatment-naïve psoriatic arthritis (PsA) and to determine whether changes in classical lipids or apolipoproteins are specific to PsA.Methods Total cholesterol, non-high-density lipoprotein cholesterol (non-HDL-c), low-density lipoprotein cholesterol (LDL-c), HDL-c, triglycerides, apolipoprotein B (ApoB) and apolipoprotein A1 (ApoA1) were compared in newly diagnosed untreated PsA patients (n=75) to sex- and age-matched controls (healthy control (HC)) (n=61) and early untreated rheumatoid arthritis (RA) patients (n=50).Results Among classical lipid measurements, HDL-c levels were lower in PsA than in HC and RA (df 2, χ210, p=0.006, PsA vs HC p=0.013). …”
Get full text

Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular Events by Mark Lebwohl, Atul Deodhar, Sergio Schwartzman, Carlo Salvarani, Meghan Feely McDonald, Natalia Bello, Elsie L. Grace, Elsa Inman, Andris Kronbergs, Marcus Ngantcha, Proton Rahman, Kim A. Papp, Joseph F. Merola, Alice B. Gottlieb, Andrew Blauvelt

“…Abstract Introduction Psoriasis (PsO), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) may confer an increased risk for cardiovascular (CV) disease, including major adverse cerebro-cardiovascular events (MACE), deep vein thrombosis (DVT), and pulmonary embolism (PE). …”
Get full text

Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial by Philip J Mease, Arthur Kavanaugh, Andreas Reimold, Hasan Tahir, Jürgen Rech, Stephen Hall, Piet Geusens, Pascale Pellet, Evie Maria Delicha, Shephard Mpofu, Luminita Pricop

“…Objective To assess the long-term (3 year) efficacy and safety of secukinumab in patients with active psoriatic arthritis (PsA) in the extension phase of the FUTURE 1 study (NCT01892436).Methods Following the 2-year core trial, eligible patients receiving subcutaneous secukinumab 150 or 75 mg entered a 3-year extension phase. …”
Get full text

Management of tuberculosis risk, screening and preventive therapy in patients with chronic autoimmune arthritis undergoing biotechnological and targeted immunosuppressive agents by Andrea Picchianti-Diamanti, Alessandra Aiello, Chiara De Lorenzo, Giovanni Battista Migliori, Delia Goletti

Subjects: Get full text

The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of Inflammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Results from a Phase III, Randomized, Placebo-Controlled Trial (PALACE 1) by Peter H. Schafer, Peng Chen, Lorraine Fang, Andrew Wang, Rajesh Chopra

“…Apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated effectiveness (versus placebo) for treatment of active psoriatic arthritis in the psoriatic arthritis long-term assessment of clinical efficacy (PALACE) phase III clinical trial program. …”
Get full text

Secukinumab-Induced Inflammatory Bowel Disease in a Patient Treated for Chronic Plaque Psoriasis and Psoriatic Arthritis: A Case Report and Review of the Role of Novel Biologic Agents Targeting the p19 Subunit of IL-23 by K. M. Darch, T. L. Holland, L. J. Spelman

“…Chronic plaque psoriasis and psoriatic arthritis are common autoimmune inflammatory conditions, often existing as comorbidities that have a significant impact on a patient’s quality of life. …”
Get full text

Spectrum of spondyloarthritis by Himanshu Pathak, Karl Gaffney

Subjects: Get full text

Onychomycosis in Psoriatic Patients with Nail Disorders: Aetiological Agents and Immunosuppressive Therapy by Núbia Carvalho Pena de Oliveira Praeiro Alves, Tomaz de Aquino Moreira, Lucivânia Duarte Silva Malvino, José Joaquim Rodrigues, Roberto Ranza, Lúcio Borges de Araújo, Reginaldo dos Santos Pedroso

“…Psoriasis and psoriatic arthritis are chronic, relapsing, immune-based diseases. …”
Get full text

Gold Finger: Metal Jewellery as a Disease Modifying Antirheumatic Therapy! by T. Hlaing, S. Ramteke, K. Binymin

“…Polyarticular psoriatic arthritis is a chronic, progressive and disabling auto-immune disease often affecting the small joints of the hands in a symmetrical fashion. …”
Get full text